[26 November 2013]
Products Affected - Description
Blephamide S.O.S ophthalmic ointment, Allergan
3.5 gm tube (NDC 00023-0313-04)
Blephamide ophthalmic suspension, Allergan
5 mL bottle (NDC 11980-0022-05)
10 mL bottle (NDC 11980-0022-10)
Reason for the Shortage
- Allergan states the reason for shortage is difficulty in obtaining the raw materials needed for manufacturing.
- Allergan is the sole supplier of sulfacetamide 10% and prednisolone 0.2% ophthalmic ointment and ophthalmic suspension.
No presentations are available.
Estimated Resupply Dates
- Allergan has Blephamide S.O.S. ophthalmic ointment on back order and the company estimates a release date in 2014.
- Allergan has Blephamide ophthalmic suspension on back order and the company estimates a release date in mid-December, 2013.
November 26, 2013; October 23, 2013; October 9, 2013; September 3, 2013; June 20, 2013, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins